22 March 2024 | Friday | News
Image Source : Public Domain
The acquisition of the full intellectual property, clients and team from MotionHall enables acceleration of multiple roadmaps, including targeted enhancements to Clarivate Cortellis™, market assessments, as well as a new Business Development & Licensing Enterprise Workbench.
Henry Levy, President, Life Sciences & Healthcare, Clarivate said: "As part of our strategy, Clarivate will enhance existing products and introduce novel solutions utilizing AI, to streamline clients' workflows and accelerate speed to insight and action. Concurrent with this transaction, the team from MotionHall has joined Clarivate to progress our on-going commitment to provide exceptional value for our clients across the entire drug, device and medical technology lifecycle."
Rachael Craig, SVP and Managing Director, Life Sciences & Healthcare Strategy Products, Clarivate, said: "Clarivate is well positioned to become a leading industry vertical artificial intelligence (AI) player. Your healthier tomorrow is being built through the successful combination of deep life sciences industry expertise and mastery of frontier AI capabilities. Clients who choose Clarivate as we advance industry vertical AI together, will have access to this frontier, becoming better equipped to deliver outcomes for their company and patients that meet today's complex challenges."
In the near-term, Clarivate will leverage MotionHall IP to further enhance Cortellis search, as well as scope of data quality and coverage.
Most Read
Bio Jobs
News